ANNEXA-I
2024
Andexanet Alfa for Acute Intracerebral Hemorrhage in Patients Receiving a Factor Xa Inhibitor
In 530 patients with factor Xa inhibitor-associated intracerebral haemorrhage, andexanet alfa improved haemostatic efficacy compared with usual care.
Result
- Absolute difference
- 13.9 points
- NNT
- 8
adjusted difference13.495% CI 4.6-22.2 · P = 0.003
Absolute difference and NNT are derived from the event rates.
Also reported: Thromboembolic events higher (10.3% vs 5.6%), including ischaemic stroke (6.5% vs 1.5%).
- Subtopic
- factor Xa reversal
- Design
- Randomised open-label RCT with blinded adjudication, stopped early
- Relevance
- Important: one of several pillars.
- Source
- Connolly SJ, et al. N Engl J Med. 2024;390(19):1745-1755.doi 10.1056/NEJMoa2313040
Discussion & critique
Improved haemostasis came with a clear excess of thromboembolic events, and functional outcomes were not improved. Stopped early for efficacy, which tempers precision and enthusiasm for routine use over PCC.